Platelet Inhibition in the Management of Thrombosis

Paul Didisheim; Francis J. Kazmier; Valentin Fuster

doi:10.1055/s-0038-1647669

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1974; 32(01): 021-034
DOI: 10.1055/s-0038-1647669

Original Article

Schattauer GmbH

Platelet Inhibition in the Management of Thrombosis^[*]

Paul Didisheim

¹Section of Laboratory Hematology, Department of Laboratory Medicine, Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic Mayo Foundation and Mayo Graduate School of Medicine, Rochester, Minnesota 55901 U.S.A.

,

Francis J. Kazmier

¹Section of Laboratory Hematology, Department of Laboratory Medicine, Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic Mayo Foundation and Mayo Graduate School of Medicine, Rochester, Minnesota 55901 U.S.A.

,

Valentin Fuster

¹Section of Laboratory Hematology, Department of Laboratory Medicine, Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic Mayo Foundation and Mayo Graduate School of Medicine, Rochester, Minnesota 55901 U.S.A.

› Author Affiliations

Abstract

Summary

The role of platelets in the initation of arterial thrombosis is clear. In venous thrombosis as well, platelets may in some circumstances play a significant role.

For these reasons, and because of the complications and limitations of anticoagulant therapy, antithrombotic trials have been launched with several agents which inhibit platelet function.

Regarding postoperative deep vein thrombosis, neither aspirin nor dipyridamole alone appears effective, although the combination offers promise. Results with the dextrans are conflicting. In recurrent idiopathic deep vein thrombosis, sulfinpyrazone may be beneficial.

On the arterial side, transient cerebral ischemic attacks may be favorably affected by either aspirin or sulfinpyrazone. Prevention of thromboembolism associated with prosthetic heart valves appears possible with combination warfarin-dipyridamole therapy, and the beneficial effect of sulfinpyrazone on shortened platelet survival in this group suggests that this agent may also be effective. Sulfinpyrazone may also be beneficial in preventing thrombosis in arteriovenous canulas.

The issue which has attracted the greatest attention and about which no clear answer exists at present is whether antiplatelet agents can modify the course of acute myocardial infarction. Several trials with aspirin are currently underway, and it would be premature to recommend its use in this condition until the results of these trials are available, probably in 1975.

Full Text

References

References
1 Acheson J, Danta G, Hutchinson E. C. 1969; Controlled trial of dipyridamole in cerebral vascular disease. British Medical Journal 01: 614.
2 Ahlberg A, Nylander G, Robertson B, Cronberg S, Nilsson I. M. 1968; Dextran prophylaxis of thrombosis in fracture of the hip. Acta Chirurgica Scandinavica Suppl. 387, 83.
3 Bang N. U, Heidenreich R. O, Trygstad C. W. 1972; Platelet adhesion. In: Bang H. J. Plasma protein requirements for human platelet aggregation 201: 280.
4 Barritt D. W, Jordan S. C. 1960; Anticoagulant drugs in treatment of pulmonary embolism: Controlled trial. Lancet 01: 1309.
5 Baumgartner H. R, Haudenschil D. C. 1972. Adhesion of platelets to sub endothelium. In: Weiss H. J. (ed.), Platelets and Their Role in Hemostasis. Annals of New York Academy of Sciences; 201 22.
6 Becker J. 1972; Postoperative venous thrombosis. Acta Chirurgica Scandinavica Suppl. 431, 7.
7 Beckering Jr R. E, Titus J. L. 1969; Femoral-popliteal venous thrombosis and pulmonary embolism. American Journal of Clinical Pathology 52: 530.
8 Blakely J. A, Gent M. 1973. Platelets, drugs and longevity in a geriatric population. In: Hirsh J. (ed.), Platelets. Drugs and Thrombosis; Karger, Basel: (in press).
9 Brisman R, Parks L. C, Haller A. J. 1970 Dextran prophylaxis of thromboembolism in high risk surgical patients. Circulation. 42. Suppl. 139 (abstract).
10 Browse N. L, Hall J. H. 1969; Effect of dipyridamole on the incidence of clinically detectable deep vein thrombosis. Lancet 02: 718.
11 Carter A. E, Eban R, Perrett R. D. 1971; Prevention of postoperative deep vein thrombosis and pulmonary embolism. British Medical Journal 01: 312.
12 Craven L. L. 1953; Experience with aspirin (acetylsalicylic acid) in nonspecific prophylaxis of coronary thrombosis. Mississippi Valley Medical Journal 75: 38.
13 Danese C. A, Voleti C. D, Weiss H. J. 1971; Protection by aspirin against experimentally induced arterial thrombosis in dogs. Thrombosis et Diathesis Haem- orrhagica 25: 288.
14 De Gaetano G, Vermylen J, Donati M. B, Dotremont G, Michielsen P. 1973. Indomethacin, platelet aggregation and renal function in chronic glomerulonephritis. Abstracts, IVth Congress, International Society on Thrombosis and Haemostasis. Vienna, Austria: 167.
15 Didisheim P. 1972. Animal models useful in the study of thrombosis and antithrombotic agents. In: Spaet T. H. (ed.), Progress in Hemostasis and Thrombosis. Vol. 1 Grune and Stratton; New York: 165.
16 Droller M. J, Wolfe S. M. 1972; Thrombin-induced increase in intracellular cyclic 3’, 5’-adenosine monophosphate in human platelets. Journal of Clinical Investigation 51: 3094.
17 Dyken M. L, Kolar O. J, Jones F. H. 1973; Differences in the occurrence of carotid transient ischemic attacks associated with antiplatelet aggregation therapy. Stroke 04: 732.
18 Evans G. 1972. Effect of platelet suppressive agents on the incidence of amaurosis fugax and transient cerebral ischemia. In: McDowell F. H , Brennan R. W. (eds.), Cerebral Vascular Diseases. Grune and Stratton; New York.:
19 Evans G, Gent M. The effect of platelet suppressive drugs on arterial and venous thromboembolism. In: Hirsh J. (Ed.), Platelets, Drugs and Thrombosis: Karger, Basel; (in press).
20 Evarts C. M. 1973. The prevention of thromboembolism by low molecular weight dextran in 500 total hip patients. Abstracts IVth International Congress on Thrombosis and Haemostasis; Vienna: 279.
21 Flanc C, Kakkar V. Y, Clarke M. B. 1968; The detection of venous thrombosis of the legs using I¹²⁵ labe lledfibrinogen. British Journal of Surgery 55: 742.
22 Foulds T, Mackinnon J. 1960; Controlled double-blind trial of “Persantin” in treatment of angina pectoris. British Medical Journal 02: 835.
23 Gent A. E, Brook C. G. D, Foley T. H, Miller T. N. 1968; Dipyridamole: a controlled trial of its effect in acute myocardial infarction. British Medical Journal 04: 366.
24 Gent M, Barnett H. J. M. 1973. The Canadian Cooperative study of recent recurrent presumed cerebral emboli (RRPCE) - A progress report. Abstracts, IVth Congress. International Society on Thrombosis and Haemostasis; Vienna, Austria: 165.
25 Goldsmith H. L. 1972. The flow of model particles and blood cells and its relation to thrombogenesis. In: Spaet T. H. (ed.), Progress in Hemostasis and Thrombosis. Vol. 1. Grune and Stratton; New York: 97.
26 Goldsmith H. L. 1974; Blood flow and thrombosis. Thrombosis et Diathesis haemor- rhagica 32: 35.
27 Harker L. A, Slichter S. 1972; Platelet and fibrinogen consumption in man. New England Journal of Medicine 287: 999.
28 Harrison M. J. G, Marshall J, Meadows J. C, Russell R. W. R. 1971; Effect of aspirin in amaurosis fugax. Lancet 02: 743.
29 Hey D. M, Burckhardt H, Heinrich D, Roka L. 1972. Antithrombotic treatment by means of ASA (aspirin) in patients with major hip joint operations: A controlled study. Abstracts, Illrd Congress. International Society on Thrombosis and Haemostasis, Washington, D. C: 42.
30 Hodam R, Starr A, Raible D, Griswold P. S. 1970; Totally cloth-covered prostheses: A review of two years’ clinical experience. Circulation, 41, Suppl 02: 33.
31 Holmsen H. 1973. Compartmentation of adenine nucleotides in platelets. In: Gerlach E, Moser K, Deutsch E, Wilmanns W. (eds.), Erythrocytes, Thrombocytes, Leukocytes. Recent advances in membrane and metabolic research. Und International Symposium. G. Thieme; Stuttgart: 321.
32 Jamieson G. A. 1973. Role of glycoproteins in platelet function. In: Gerlach E, Moser K, Deutsch E, Wilmanns W. (eds.), Erythrocytes, Thrombocytes, Leukocytes. Recent advances in membrane and metabolic research. Und International Symposium. G. Thieme; Stuttgart: 209.
33 Kaegi M. B, Pineo G. F, Shimizu A, Trivedi H, Hirsh J, Gent M. 1974; Arteriovenous - shunt thrombosis. Prevention by sulfinpyrazone. New England Journal of Medicine 290: 304.
34 Kakkar y. Y, Howe C. T, Flanc C, Clarke M. B. 1969; Natural history of postoperative deep-vein thrombosis. Lancet 02: 230.
35 Kakkar y. y, Howe C. T, Nicolaides A. N, Renney J. T. G, Clarke M. B. 1970; Deep vein thrombosis of the leg : Is there a high risk group ?. American Journal of Surgery 120: 527.
36 Kincaid-Smith P. 1969; Modification of the vascular lesions of rejection in cadaveric renal allografts by dipyridamole and anticoagulants. The Lancet 02: 920.
37 Lambie J. M, Barber D. C, Dhall D. P, Matheson N. A. 1970; Dextran 70 in prophylaxis of postoperative venous thrombosis. British Medical Journal 02: 144.
38 Lévy-Toledano S, Rendu F, Bodevin E, Caen J. P. 1973. Apyrase, albumin, gamma-globulins and fibrinogen requirement for human gel-filtered platelet aggregation. In: Gerlach E, Moser K, Deutsch E, Wilmanns W. (eds.), Erythrocytes, Thrombocytes, Leukocytes. Recent advances in membrane and metabolic research. Ilnd International Symposium. G. Thieme; Stuttgart: 303.
39 McDonald J. W. D, Stuart R. K. 1973; Regulation of cyclic AMP levels and aggregation in human platelets by prostaglandin, E_x . Journal of Laboratory and Clinical Medicine 81: 838.
40 Mundall J, Quintero P, von Kaulla K, Austin J, Harmon R. 1971; Transient monocular blindness and increased platelet aggregability treated with aspirin - a case report. Neurology 21: 402.
41 Mustard J. F, Packham M. A. 1970; Factors influencing platelet function: adhesion, release and aggregation. Pharmacological Reviews 22: 97.
42 Mustard J. F, Kinlough-Rathbone R. L, Jenkins C. S. P, Packham M. A. 1972; Modification of platelet function. In: Weiss, H. J 201: 343.
43 O’Brien J. R. 1973; The mechanisms of venous thrombosis. Modern Concepts of Cardiovascular Diseases 42: 11.
44 O’Brien J. R, Tulevski V, Etherington M. 1971; Two in vivo studies comparing high and low aspirin dosage. Lancet 01: 399.
45 O’Sullivan E. F, Renney J. T. G. 1972. Anti-platelet drugs in the prevention of post-operative deep vein thrombosis. Abstracts, lllrd Congress International Society on Thrombosis and Haemostasis. Washington, D. C: 438.
46 O’Sullivan E. F, Vellar I. D. A. 1972. Assessment of the efficacy of antiplatelet drugs in the prevention of experimental venous thrombosis in the rabbit. Abstracts, lllrd Congress International Society on Thrombosis and Haemostasis. Washington, D. C: 440.
47 Packham M. A, Guccione M. A, Chang P-L, Mustard J. F. 1973; Platelet aggregation and release: effects of low concentrations of thrombin or collagen. American Journal of Physiology 225: 38.
48 Paterson J. C. 1969. The pathology of venous thrombi. In: Sherry S, Brinkhous K. M, Genton E, Stengle J. M. (eds.), Thrombosis. National Academy of Sciences: Washington, D. C; 321.
49 bReport of the Steering Committee of a Trial Sponsored by the Medical Research Council. 1972; Effect of aspirin in postoperative venous thrombosis. Lancet 02: 441.
50 Roberts W. C, Buja L. M. 1972; The frequency and significance of coronary arterial thrombi and other observations in fatal acute myocardial infarction. A study of 107 necropsy patients. American Journal of Medicine 52: 425.
51 Salzman E. W, Harris W. H, De Sanctis R. W. 1971; Reduction in venous thromboembolism by agents affecting platelet function. New England Journal of Medicine 284: 1287.
52 Salzman E. W, Kensler P. D, Levine L. 1972; Cyclic 3’, 5’-adenosine monophosphate in human blood platelets. IV. Regulatory role of cyclic AMP in platelet function. In: Weiss, H. J 201: 61.
53 Sbar S, Schlant R. C. 1967; Dipyridamole in the treatment of angina pectoris. A double-blind evaluation. Journal of the American Medical Association 201: 865.
54 Schwartz M. L, Sheldon A, Dorman F, Blackshear P. L, Varco R. L, Btjchwold H, Nicoloff D. M. 1973; Local anticoagulation of prosthetic heart valves. Circulation 48 Suppl. I, III-85.
55 Sevitt S, Gallagher N. 1961; Venous thrombosis and pulmonary embolism. A clinico-pathological study in injured and burned patients. The British Journal of Surgery 48: 475.
56 Soloff L. A, Gimenez J. L, Winters Jr W. L. 1962; Experimental and clinical observations on 2,6-bis (diethanolamino)-4,8-dipiperidino-pyrimido-(5,4-d) pyrimidine (Persantin). American Journal of Medical Sciences 243: 783.
57 Spaet T. H, Stemerman M. B. 1972; Platelet adhesion. In: Weiss, H. J 201: 13.
58 Steele P. P, Weily H. S, Genton E. 1973; Platelet survival and adhesiveness in recurrent venous thrombosis. New England Journal of Medicine 288: 1148.
59 Sullivan J. M, Harken D. E, Gorlin R. 1971; Pharmacologic control of thromboembolic complications of cardiac-valve replacement. New England Journal of Medicine 284: 1391.
60 Sutor A. H, Schindera F, Jacobi H, Künzer W. 1972; Haemolytic-uremic syndrome : thrombocyturia after treatment with streptokinase and aspirin. The Lancet 02: 762.
61 Weber W, Wolff V, Bromig G. 1971; Postoperative Thrombo-embolie - Prophylaxe mit Colfarit R. Therapeutische Berichte 43: 229.
62 Weily H. S, Genton E. 1970; Altered platelet function in patients with prosthetic mitral valves. Effects of sulfinpyrazone therapy. Circulation 42: 967.
63 Weiss H. J. 1972. The pharmacology of platelet inhibition. In: Spaet T. H. (ed.), Progress in Hemostasis and Thrombosis. Vol. 1, Grune and Stratton; New York: 199.
64 Weiss J. A. 1967; The effect of clinical dextran on platelet aggregation, adherence and ADP release in man; in vivo and in vitro studies. Journal of Laboratory and Clinical Medicine 69: 37.
65 Wells Jr R. E. 1964; Rheology of blood in the micro vasculature. New England Journal of Medicine 270: 889.
66 Wessler S, Yin E. T. 1973; Theory and practice of minidose heparin in surgical patients. Circulation 47: 671.
67 Wilner G. D, Nossel H. L, Le Roy E. C. 1968; Aggregation of platelets by collagen. Journal of Clinical Investigation 47: 2616.
68 Yin E. T, Giudice L. C, Wessler S. 1973; Inhibition of activated factor X- induced platelet aggregation : the role of heparin and the plasma inhibitor to activated factor X. Journal of Laboratory and Clinical Medicine 82: 390.
69 Zekert P, Kohn P, Vormitting E. 1973. Prophylaxis of thromboembolic diseases in traumatologic patients. Abstracts, IVth Congress, International Society on Thrombosis and Haemostasis. Vienna, Austria: 281.
70 Zion M. M, Bradlow B. A. 1961; A controlled clinical trial of “Persantin” (RA 8) in angina pectoris. South African Medical Journal 35: 11.

Platelet Inhibition in the Management of Thrombosis[*]

Platelet Inhibition in the Management of Thrombosis^[*]